PDCD1 and cancer: In conclusion, our results provide multiple levels of evidence that SHP-2 and the PD-1-SHP-2 axis pose a signaling restrain to the differentiation and monocyte/DC lineage in the context of cancer, resulting in a myeloid landscape that compromises antitumor immunity.